About The Study: The findings of this study of 68,000 patients who received a diagnosis of COVID-19 and who were at high risk of progressing to severe COVID-19 suggest that the use of either nirmatrelvir (Paxlovid) or molnupiravir (Lagevrio) is associated with reductions in mortality and hospitalization in patients infected with Omicron, regardless of age, race and ethnicity, virus strain, vaccination status, previous infection status, or coexisting conditions. Both drugs can, therefore, be used to treat non-hospitalized patients who are at high risk of progressing to severe COVID-19.
Authors: Dan-Yu Lin, Ph.D., of the University of North Carolina in Chapel Hill, and Xiaofeng Wang, Ph.D., of the Cleveland Clinic, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.35077)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.35077?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092123
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open